Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10)

Potential synthetic lethal lead, targeting E-cadherin-deficient cells

Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19

Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits.

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation

Specific Inhibitor of Skp2-Mediated p27 Degradation

Specific Inhibitor of Skp2-Mediated p27 Degradation

Novel inhibitor of OLIG2 in glioblastoma

Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells

Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML

Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase

Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK

Biological Active Reagents

Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin

Novel inhibitor of NF

Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin

Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV)

Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization

Selective, brain penetrant 5-HT(1B/D) receptor agonist

Dopamine D1 receptor agonist

Inhibitor of Aβ self-aggregation

Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry

Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity

Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication)

Novel selective EGFR degrader

Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells

Novel selective MDMX antagonist

Novel Inhibitor of the Disordered Protein, p27(Kip1)